Payment overview · 2025
General Payments
$965.90
47 reported records · 8 companies
Healthcare provider profile · identity verified
Michael David Schwartz, D.O.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · COSTA MESA, CA · NPI 1861584708
Verified facts
What the public records show
CMS Open Payments records show Michael David Schwartz, D.O. received $965.90 in general payments during 2025 across 47 reported records.
Neurocrine BioSciences, Inc. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Invega Sustenna.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Invega Sustenna by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $254.79 | 26.4% | 16 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $235.67 | 24.4% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $173.59 | 18.0% | 8 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $112.10 | 11.6% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $84.36 | 8.7% | 3 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $55.96 | 5.8% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.44 | 2.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.99 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $965.90 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $254.79 | 16 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $235.67 | 9 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $235.67 | 9 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $173.59 | 8 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $94.82 | 5 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $84.36 | 3 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $55.96 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $26.44 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clozapine | Clozapine | 149 | 15 |
| Gabapentin | Gabapentin | 135 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 135 | 29 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 110 | 30 |
| Divalproex Sodium | Divalproex Sodium | 97 | 20 |
| Clonazepam | Clonazepam | 92 | 17 |
| Olanzapine | Olanzapine | 83 | 15 |
| Sertraline Hcl | Sertraline Hcl | 79 | 12 |
| Trazodone Hcl | Trazodone Hcl | 62 | 18 |
| Propranolol Hcl | Propranolol Hcl | 54 | 12 |
| Aripiprazole | Aripiprazole | 51 | 11 |
| Lamotrigine | Lamotrigine | 51 | suppressed |
| Austedo Xr | Deutetrabenazine | 43 | suppressed |
| Metformin Hcl | Metformin Hcl | 43 | 15 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 36 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 29 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $965.90 · 47 records | Neurocrine BioSciences, Inc. | ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, COBENFY, ERZOFRI EXTENDED-RELEASE, FANAPT, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, LYBALVI, UZEDY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error